CONTACT US

Ontoria JM, Altamura S, Di Marco A, Ferrigno F, Laufer R, Muraglia E, Palumbi MC, Rowley M, Scarpelli R, Schultz-Fademrecht C, Serafini S, Steinkühler C, Jones P. (2009) Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. J Med Chem. 2009 Nov 12;52(21):6782-9.

Ontoria JM, Rydberg EH, Di Marco S, Tomei L, Attenni B, Malancona S, Martin Hernando JI, Gennari N, Koch U, Narjes F, Rowley M, Summa V, Carroll SS, Olsen DB, De Francesco R, Altamura S, Migliaccio G, Carfì A. (2009) Identification and biological evaluation of a series of 1H-benzo[de]isoquinoline-1,3(2H)-diones as hepatitis C virus NS5B polymerase inhibitors. J Med Chem. 2009 Aug 27;52(16):5217-27.

Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, Lamartina S, Monteagudo E, Ontoria JM, Orsale MV, Palumbi MC, Pesci S, Roscilli G, Scarpelli R, Schultz-Fademrecht C, Toniatti C, Rowley M. (2009) Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.

Pacini B, Avolio S, Ercolani C, Koch U, Migliaccio G, Narjes F, Pacini L, Tomei L, Harper S. (2009) 2-(3-Thienyl)-5,6-dihydroxypyrimidine-4-carboxylic acids as inhibitors of HCV NS5B RdRp. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6245-9.

Gardelli C, Attenni B, Donghi M, Meppen M, Pacini B, Harper S, Di Marco A, Fiore F, Giuliano C, Pucci V, Laufer R, Gennari N, Marcucci I, Leone JF, Olsen DB, MacCoss M, Rowley M, Narjes F. (2009) Phosphoramidate prodrugs of 2′-C-methylcytidine for therapy of hepatitis C virus infection. J Med Chem. 2009 Sep 10;52(17):5394-407.

Dharmapuri S, Peruzzi D, Aurisicchio L. (2009) Engineered adenovirus serotypes for overcoming anti-vector immunity. Expert Opin Biol Ther. 2009 Oct;9(10):1279-87.

Orsatti L, Forte E, Tomei L, Caterino M, Pessi A, Talamo F. (2009) 2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets. Electrophoresis. 2009 Jul;30(14):2469-76.

Orsatti L, Innocenti F, Lo Surdo P, Talamo F, Barbato G. (2009) Mass spectrometry study of PRL-3 phosphatase inactivation by disulfide bond formation and cysteine into glycine conversion. Rapid Commun Mass Spectrom. 2009 Sep;23(17):2733-40.

Harper S, Ferrara M, Crescenzi B, Pompei M, Palumbi MC, DiMuzio JM, Donghi M, Fiore F, Koch U, Liverton NJ, Pesci S, Petrocchi A, Rowley M, Summa V, Gardelli C. (2009) Inhibitors of the hepatitis C virus NS3 protease with basic amine functionality at the P3-amino acid N-terminus: discovery and optimization of a new series of P2-P4 macrocycles. J Med Chem. 2009 Aug 13;52(15):4820-37.

Dharmapuri S, Peruzzi D, Mennuni C, Calvaruso F, Giampaoli S, Barbato G, Kandimalla ER, Agrawal S, Scarselli E, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L. (2009) Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. Mol Ther. 2009 Oct;17(10):1804-13.

Cadot B, Brunetti M, Coppari S, Fedeli S, de Rinaldis E, Dello Russo C, Gallinari P, De Francesco R, Steinkühler C, Filocamo G. (2009) Loss of histone deacetylase 4 causes segregation defects during mitosis of p53-deficient human tumor cells. Cancer Res. 2009 Aug 1;69(15):6074-82.

Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V. (2009) Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4617-21.

Fonsi M, Fiore F, Jones P, Kinzel O, Laufer R, Rowley M, Monteagudo E. (2009) Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate. Xenobiotica. 2009 Oct;39(10):722-37.

Branca D, Cerretani M, Jones P, Koch U, Orvieto F, Palumbi MC, Rowley M, Toniatti C, Muraglia E. (2009) Identification of aminoethyl pyrrolo dihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4042-5.
Orvieto F, Branca D, Giomini C, Jones P, Koch U, Ontoria JM, Palumbi MC, Rowley M, Toniatti C, Muraglia E. (2009) Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4196-200.

Dessole G, Branca D, Ferrigno F, Kinzel O, Muraglia E, Palumbi MC, Rowley M, Serafini S, Steinkühler C, Jones P. (2009) Discovery of N-[(1-aryl-1H-indazol-5-yl)methyl]amides derivatives as smoothened antagonists for inhibition of the hedgehog pathway. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4191-5.

Petrocchi A, Jones P, Rowley M, Fiore F, Summa V. (2009) N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4245-9.

Mattu M, Bendtsen C, Barbato G. (2009) An indirect method to measure trimerization constants using surface plasmon resonance. Anal Biochem. 2009 Oct 1;393(1):126-8.

Meppen M, Pacini B, Bazzo R, Koch U, Leone JF, Koeplinger KA, Rowley M, Altamura S, Di Marco A, Fiore F, Giuliano C, Gonzalez-Paz O, Laufer R, Pucci V, Narjes F, Gardelli C. (2009) Cyclic phosphoramidates as prodrugs of 2′-C-methylcytidine. Eur J Med Chem. 2009 Sep;44(9):3765-70.

Kinzel O, Llauger-Bufi L, Pescatore G, Rowley M, Schultz-Fademrecht C, Monteagudo E, Fonsi M, Gonzalez Paz O, Fiore F, Steinkühler C, Jones P. (2009) Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. J Med Chem. 2009 Jun 11;52(11):3453-6.

Attenni B, Ontoria JM, Cruz JC, Rowley M, Schultz-Fademrecht C, Steinkühler C, Jones P. (2009) Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3081-4.

Gallinari P, Filocamo G, Jones P, Pazzaglia S, Steinkühler C. (2009) Smoothened antagonists: a promising new class of antitumor agents. Expert Opin Drug Discov. 2009 May;4(5):525-44.

Bianchi E, Ingallinella P, Finotto M, Liang X, Kinney GG, Pessi A. (2009) A peptide vaccine based on retro-inverso beta-amyloid sequences fails to elicit a cross-reactive immune response. Adv Exp Med Biol. 2009;611:363-4.

Bianchi E, Finotto M, Ingallinella P, Citron M, Hrin R, Lu M, Geleziunas R, Miller MD, Liang X, Pessi A. (2009) A strategy for selectively shielding portions of a peptide/protein from immune response while maintaining immunogenicity of contiguous epitopes. Adv Exp Med Biol. 2009;611:359-60.

Bianchi E, Ingallinella P, Finotto M, Joyce J, Liang X, Miller MD, Kinney GG, Ciliberto G, Shiver JW, Pessi A. (2009) Synthetic peptide vaccines: the quest to develop peptide vaccines for influenza, HIV and Alzheimer’s disease. Adv Exp Med Biol. 2009;611:121-3.

Pompei M, Francesco ME, Koch U, Liverton NJ, Summa V. (2009) Phosphorous acid analogs of novel P2-P4 macrocycles as inhibitors of HCV-NS3 protease. Bioorg Med Chem Lett. 2009 May 1;19(9):2574-8.

Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J, Palombo F, Viti V, Mesiti G, Zappulli V, Marconato L, Abramo F, Ciliberto G, Lahm A, La Monica N, de Rinaldis E. (2009) Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics. 2009 Mar 27;10:135.

Avolio S, Robertson K, Hernando JI, DiMuzio J, Summa V. (2009) Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2295-8.

Donghi M, Kinzel OD, Summa V. (2009) 3-Hydroxy-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxylates–a new class of HIV-1 integrase inhibitors. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1930-4.

Donghi M, Attenni B, Gardelli C, Marco AD, Fiore F, Giuliano C, Laufer R, Leone JF, Pucci V, Rowley M, Narjes F. (2009) Synthesis and evaluation of novel phosphoramidate prodrugs of 2′-methyl cytidine as inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1392-5.

Peruzzi D, Dharmapuri S, Cirillo A, Bruni BE, Nicosia A, Cortese R, Colloca S, Ciliberto G, La Monica N, Aurisicchio L. (2009) A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine. 2009 Feb 25;27(9):1293-300.

Habermann J, Capitò E, Ferreira Mdel R, Koch U, Narjes F. (2009) Discovery of pentacyclic compounds as potent inhibitors of hepatitis C virus NS5B RNA polymerase. Bioorg Med Chem Lett. 2009 Feb 1;19(3):633-8.

Dharmapuri S, Aurisicchio L, Neuner P, Verdirame M, Ciliberto G, La Monica N. (2009) An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models. Cancer Gene Ther. 2009 May;16(5):462-72.

Scarpelli R, Di Marco A, Ferrigno F, Laufer R, Marcucci I, Muraglia E, Ontoria JM, Rowley M, Serafini S, Steinkühler C, Jones P. (2008) Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6078-82.

Mori F, Giannetti P, Peruzzi D, Lazzaro D, Giampaoli S, Kaufman HL, Ciliberto G, La Monica N, Aurisicchio L. (2009) A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. Hum Gene Ther. 2009 Feb;20(2):125-36.